Piper methysticum G.Forst: A Potent Antianxiety Agent

  • Amritpal Singh Saroya
  • Jaswinder Singh

















  1. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med. 1996;125:940–1.CrossRefPubMedGoogle Scholar
  2. Balick MJ, Roberta L. Traditional use of sakau (kava) in Pohnpei: lessons for integrative medicine. Alter Thera. 2000;8:96.Google Scholar
  3. Bilia AR, Gallon S, Vincieri FF. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci. 2002;70:2581–97.CrossRefPubMedGoogle Scholar
  4. Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M. Kava-kava extract LI 150 is as effective as Opipramol and Buspirone in generalised anxiety disorder--an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine. 2003;10(Suppl 4):38–49.CrossRefPubMedGoogle Scholar
  5. Cagnacci A, Arangino S, Renzi A, Zanni AL, Malmusi S, Volpe A. Kava-Kava administration reduces anxiety in perimenopausal women. Maturitas. 2003;44:103–9.CrossRefPubMedGoogle Scholar
  6. Chua HC, Christensen ET, Hoestgaard-Jensen K, Hartiadi LY, Ramzan I, Jensen AA, Absalom NL, Chebib M. Kavain, the major constituent of the anxiolytic kava extract, potentiates GABAA receptors: functional characteristics and molecular mechanism. PLoS One. 2016;11:e0157700.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Connor KM, Payne V, Davidson JR. Kava in generalized anxiety disorder: three placebo-controlled trials. Int Clin Psychopharmacol. 2006;21:249–53.CrossRefPubMedGoogle Scholar
  8. De Leo V, La Marca A, Lanzetta D, Palazzi S, Torricelli M, Facchini C, Morgante G. Assessment of the association of Kava-Kava extract and hormone replacement therapy in the treatment of postmenopause anxiety. Minerva Ginecol. 2000;52:263–7.PubMedGoogle Scholar
  9. Dentali SJ. Herb safety review. Kava. Piper methysticum Forster f. (Piperaceae). Boulder: Herb Research Foundation, 1997;29 pp.Google Scholar
  10. Dragull K, Yoshida WY, Tang CS. Piperidine alkaloids from Piper methysticum. Phytochemistry. 2003;63:193–8.CrossRefPubMedGoogle Scholar
  11. Feltenstein MW, Lambdin LC, Ganzera M, Ranjith H, Dharmaratne W, Nanayakkara NP, Khan IA, Sufka KJ. Anxiolytic properties of Piper methysticum extract samples and fractions in the chick social-separation-stress procedure. Phytother Res. 2003;17:210–6.CrossRefPubMedGoogle Scholar
  12. Furgiele AR, Farnsworth NR, Buckley JP. False-positive alkaloid reactions obtained with extracts of Piper methysticum. J Pharm Sci. 1962;51:1156–62.CrossRefGoogle Scholar
  13. Garner LF, Klinger JD. Some visual effects caused by the beverage kava. J Ethnopharmacol. 1985;13:307–11.CrossRefPubMedGoogle Scholar
  14. Garrett KM, Basmadjian G, Khan IA, Schaneberg BT, Seale TW. Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice. Psychopharmacology. 2003;170:33–41.CrossRefPubMedGoogle Scholar
  15. Geier FP, Konstantinowicz T. Kava treatment in patients with anxiety. Phytother Res. 2004;18:297–300.CrossRefPubMedGoogle Scholar
  16. Grunze H, Langosch J, Schirrmacher K, Bingmann D, Von Wegerer J, Walden J. Kava pyrones exert effects on neuronal transmission and transmembraneous cation currents similar to established mood stabilizers-a review. Prog Neuro-Psychopharmacol Biol Psychiatr. 2001;25:1555–70.CrossRefGoogle Scholar
  17. Holmes LD. Piper methysticium (kava). The function of kava in modern Samoan culture. Psychopharmacol Bull. 1967;4:9.PubMedGoogle Scholar
  18. Kinder C, Cupp MJ. Kava: an herbal sedative. Nurse Pract. 1998;14(156):23.Google Scholar
  19. Kinzler E, Krömer J, Lehmann E. Effect of a special kava extract in patients with anxiety-, tension, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks. Arzneimittelforschung. 1991;41:584–8.PubMedGoogle Scholar
  20. Klohs MW, Keller F, Willimas RE, et al. A chemical and pharmacological investigation of Piper methysticum Forst. J Medication Pharm Chem. 1959;1:95–103.CrossRefGoogle Scholar
  21. Kretschmer W. Kavain as a psychopharmacologic agent. Munch Med Wochenschr. 1970;112:154–8.PubMedGoogle Scholar
  22. Kretschmer W. Mental effects of kavain. MMW Munch Med Wochenschr. 1974;116:741–2.PubMedGoogle Scholar
  23. Lebot V, Merlin M, Lindstrom L. Kava: The Pacific drug. New Haven: Yale University Press, 1992.; 255 pp.Google Scholar
  24. Lehmann E, Kinzler E, Friedemann J. Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin – a double-blind placebo-controlled study of four weeks treatment. Phytomedicine. 1996;3:113–9.CrossRefPubMedGoogle Scholar
  25. Lehrl S. Clinical efficacy of kava extracts WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. J Affect Disord. 2004;78:101–10.CrossRefPubMedGoogle Scholar
  26. Lemert EM. Secular use of kava in Tonga. Q J Stud Alcohol. 1967;28:328–41.PubMedGoogle Scholar
  27. Lemert EM. Koni, kona, kava. Orange-beer culture of the Cook Islands. J Stud Alcohol. 1976;37:565–85.CrossRefPubMedGoogle Scholar
  28. Lindenberg D, Pitule-Schödel H. D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness. Fortschr Med 1990;108:49–50., 53-4.Google Scholar
  29. Meyer HJ. A study of anticonvulsant properties of the kava pyrones dihydromethysticin and dihydrokavain in chemically induced convulsions. Arch Int Pharmacodyn Ther. 1964;150:118–31.PubMedGoogle Scholar
  30. Meyer HJ, Meyer-Burg J. Inhibition of electroconvulsions by kava-pyrones dihydromethysticin and dihydrokavain. Arch Int Pharmacodyn Ther. 1964;148:97–110.PubMedGoogle Scholar
  31. Müller B, Komorek R. Treatment with Kava-the root to combat stress. Wien Med Wochenschr. 1999;149:197–201.PubMedGoogle Scholar
  32. Nowakowska E, Ostrowicz A, Chodera A. Kava-kava preparations-alternative anxiolytics. Pol Merkur Lekarski. 1998;4:179–80.PubMedGoogle Scholar
  33. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2002;2:CD003383.Google Scholar
  34. Readon E. A drug from Polynesia with central nervous activity: Piper methysticum Forst (“kava-kava”). Gazz Med Ital. 1960;119:231–3.Google Scholar
  35. Riesenberg SH. Ancient kava ceremony re-enacted on Pahn Kedira, Ponape. Psychopharmacol Bull. 1967;4:5–8.PubMedGoogle Scholar
  36. Saeed SA, Bloch RM, Antonacci DJ. Safety of kava for patients with mild anxiety disorders. Am Fam Physician. 2008;78:433–4.PubMedGoogle Scholar
  37. Sarris J, Kavanagh DJ, Byrne G, Bone KM, Adams J, Deed G. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology. 2009;205:399–407.CrossRefPubMedGoogle Scholar
  38. Sarris J, Stough C, Bousman CA, Wahid ZT, Murray G, Teschke R, Savage KM, Dowell A, Ng C, Schweitzer I. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2013;33:643–8.CrossRefPubMedGoogle Scholar
  39. Scherer J. Kava-kava extract in anxiety disorders: an outpatient observational study. Adv Ther. 1998;15:261–9.PubMedGoogle Scholar
  40. Schliack H. Kavain in diseases of the aged. Hippokrates. 1967;38:26–30.PubMedGoogle Scholar
  41. Schmidt N, Ferger B. Neuroprotective effects of (+/−)-kavain in the MPTP mouse model of Parkinson’s disease. Synapse. 2001;40:47–54.CrossRefPubMedGoogle Scholar
  42. Shulgin AT. The narcotic pepper – the chemistry and pharmacology of Piper methysticum and related species. Bull Narc. 1973;25:59–74.Google Scholar
  43. Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs. 2002;16:731–43.CrossRefPubMedGoogle Scholar
  44. Smith KK, Dharmaratne HR, Feltenstein MW, Broom SL, Roach JT, Nanayakkara NP, Khan IA, Sufka KJ. Anxiolytic effects of kava extract and kavalactones in the chick social separation-stress paradigm. Psychopharmacology. 2001;155:86–90.CrossRefPubMedGoogle Scholar
  45. Tawfiq RA, Nassar NH, El-Eraky WI, El-Denshary S. E. Enhanced efficacy and reduced side effects of diazepam by kava combination. J Adv Res. 2014;5:587–94.CrossRefPubMedGoogle Scholar
  46. Tsutsui R, Shinomiya K, Takeda Y, Obara Y, Kitamura Y, Kamei C. Hypnotic and sleep quality-enhancing properties of kavain in sleep-disturbed rats. J Pharmacol Sci. 2009;111:293–8.CrossRefPubMedGoogle Scholar
  47. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry. 1998;31:187–92.CrossRefPubMedGoogle Scholar
  48. Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders-a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry. 1997;30:1–5.CrossRefPubMedGoogle Scholar
  49. Wagner WL, Herbst DR, Sohmer SH. Manual of the flowering plants of Hawai‘i. 2 vols. Honolulu: University of Hawaii Press & Bishop Museum Press; 1990.Google Scholar
  50. Wheatly D. Stress-induced insomnia treated with kava and valerian. Hum Psychopharmacol. 2001;16:353–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Amritpal Singh Saroya
    • 1
  • Jaswinder Singh
    • 2
  1. 1.Herbal ConsultantMohaliIndia
  2. 2.Department of PharmacologySri Guru Ram Das Institute of Medical ScienceAmritsarIndia

Personalised recommendations